Nombre del producto:N-Boc-piperazine

IUPAC Name:tert-butyl piperazine-1-carboxylate

Fórmula molecular:C9H18N2O2
Número de catálogo:CM103943
Peso molecular:186.26

Unidad de embalaje Stock disponible Precio($) Cantidad
CM103943-500g in stock ƤȌ
CM103943-1000g in stock Ǖſſ

Sólo para uso en I+D..

Formulario de consulta


Detalles del producto

Núm. De CAS :57260-71-6
Fórmula molecular:C9H18N2O2
Punto de fusión:-
Código de sonrisas:CC(C)(C)OC(=O)N1CCNCC1
Número de catálogo:CM103943
Peso molecular:186.26
Punto de ebullición:
Nº Mdl:MFCD00075265

Category Infos

PROTACs (Proteolytic Targeting Chimeric Molecules) are heterobifunctional protein degraders and are promising targeted therapy candidates for cancer. PROTAC is composed of three parts, one end is connected with the ligand bound by E3 ligase, the other end is connected with the ligand bound by the target protein, and the middle is the linker.
Protac Linkers
where to buy PROTAC-Linkers, Chemenu is research-based manufacturer of pharmaceutical intermediates. We supply Protac Linkers with low price.Warmly welcome new and old customers to visit!

Column Infos

Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Blueprint Medicines announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.  AYVAKYT was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous recombination repair (HRR)-deficient breast cancers, according to results from the phase I/II PETRA trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.
Saruparib, a PARP1-specific inhibitor, showed promising tumor growth inhibition in preclinical models of breast, ovarian, pancreatic, and prostate cancer harboring HRR deficiency mutations. Because saruparib was less toxic than other PARP inhibitors, it could be given at higher doses.